Pharmaceutical Business review

FDA rejects Summit’s ivonescimab application for lung cancer

Although ivonescimab achieved a PFS benefit, the FDA determined this did not support a favourable benefit-risk balance. Credit: Sai Thaw Kyar/Shutterstock.com.

The regulator notified the company of its decision in a complete response letter (CRL).

Summit Therapeutics had sought approval for the investigational drug, in combination with platinum-containing chemotherapy, to treat patients whose NSCLC had progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor therapy.

The FDA said the application could not be approved in its current form, concluding that Summit had not established substantial evidence of effectiveness without a statistically significant improvement in overall survival.

Although ivonescimab achieved a progression-free survival (PFS) benefit in the global Phase III HARMONi clinical trial (NCT06396065), the FDA determined that this finding did not support a favourable benefit-risk balance without a survival gain.

The primary overall survival analysis showed a positive trend but did not achieve statistical significance. Currently, no treatments approved by the FDA have demonstrated a statistically significant overall survival benefit in this subset of NSCLC patients.

Summit Therapeutics president and co-CEO Maky Zanganeh said: “As a cancer survivor, I understand firsthand how important it is for patients to have access to multiple treatment options, particularly when they are facing diseases with significant unmet medical needs.

“Behind every diagnosis is a person, a family, and a community hoping for more time, more possibilities, and a better future. I know that hope is not simply an emotion; it is the possibility that another treatment, another scientific breakthrough, or another therapeutic option may make a meaningful difference in someone’s life.

“Every additional treatment option matters. It represents another opportunity for patients and their families, especially those who have exhausted existing therapies or have limited alternatives.”

Safety findings from the Phase III study showed that 16 patients (7.3%) discontinued ivonescimab due to treatment-related adverse events, compared with 11 patients (5.0%) who discontinued placebo.

Deaths resulting from treatment-related adverse events occurred in four patients (1.8%) receiving ivonescimab with chemotherapy and five patients (2.3%) receiving chemotherapy alone.

Ivonescimab was developed by Akeso and received marketing authorisation for NSCLC patients with EGFR gene mutations that progressed after EGFR-TKI treatment in China in May 2024.

The programmed cell death protein-1 (PD-1) x vascular endothelial growth factor (VEGF) bispecific antibody remains investigational and unapproved across Summit’s licence territories, which include Europe and the US.

To date, the FDA has not approved any PD-1 x VEGF bispecific antibodies.

Exit mobile version